Summary & Overview
HCPCS J9229: Inotuzumab Ozogamicin Injection, 0.1 mg
HCPCS Level II code J9229 denotes inotuzumab ozogamicin, an antibody–drug conjugate administered intravenously and billed per 0.1 mg. The code matters nationally because it supports consistent billing for a high-cost oncology injectable used in specific hematologic malignancies; accurate coding affects reimbursement, prior authorization workflows, and cost reporting across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for inotuzumab ozogamicin, how the HCPCS Level II code maps to dosage-based billing, and typical sites of service where doses are administered. The publication presents national benchmarks for coverage and payment variability across major payers, summarizes applicable policy considerations and prior authorization trends, and outlines common billing elements and modifiers used alongside J9229.
This summary equips billing managers, revenue cycle staff, and policy analysts with the information needed to align coding practices with payer requirements, manage high-cost drug workflows, and anticipate administrative steps tied to infusion services for oncology patients.
Billing Code Overview
HCPCS Level II code J9229 represents an injectable oncology medication: inotuzumab ozogamicin, billed per 0.1 mg unit. This code is used when the drug is delivered as an intravenous injection for oncology treatment.
-
Service type: Drug administration (intravenous injection)
-
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or other outpatient infusion setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (ALL) being treated in an oncology infusion center or hospital outpatient clinic. The patient presents for scheduled intravenous administration of inotuzumab ozogamicin as part of a weight‑based or vial‑based dosing regimen. Pre‑infusion evaluation includes verification of diagnosis, recent labs (CBC, liver function tests), review of prior infusion reactions, and assessment for contraindications such as hepatic impairment or active infection. Nursing establishes venous access (peripheral IV or implanted port), administers premedication per protocol if indicated, and monitors vital signs and infusion tolerance. The medication, billed as J9229 per 0.1 mg units, is prepared by pharmacy under sterile compounding standards with documentation of lot numbers and any wasted drug for potential JW or JZ modifier reporting. During and after infusion, the patient is observed for infusion‑related reactions, hepatotoxicity, and cytopenias, with follow‑up labs and oncology visits scheduled according to the treatment protocol. Discharge instructions include reporting signs of infection, hepatic dysfunction, or bleeding.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |